RNAnalytics

RNAnalytics

Vienna, Austria· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.7M

Overview

RNAnalytics is building an operating system for RNA nanoparticle analytics, addressing critical bottlenecks in characterization and regulatory filing for lipid nanoparticle (LNP)-based therapeutics. Its wedge product, RNABOX, is a consumable toolkit for standardized wet-lab execution on existing instruments, starting with nanoparticle sizing and followed by an encapsulation efficiency module. The complementary RNAOS software platform automates workflows, ensures auditability, and structures data for regulatory submission, aiming to capture margin and defensibility as adoption grows. The company is in early commercial traction with paid pilots and plans a full platform launch.

Drug Delivery

Technology Platform

Integrated platform combining validated physical toolkits (RNABOX) for standardized wet-lab nanoparticle analytics with a cloud-native software hub (RNAOS) for workflow automation, audit trails, and CTD-aligned regulatory reporting.

Funding History

2
Total raised:$1.7M
Grant$500K
Seed$1.2M

Opportunities

The rapid growth of the RNA/LNP therapeutics market creates strong demand for standardized, reproducible analytics to accelerate development and ensure regulatory compliance.
CDMOs, as centralized service providers for multiple drug developers, represent a high-value, concentrated customer segment eager for solutions that improve efficiency and auditability across client programs.

Risk Factors

Key risks include commercialization challenges in displacing entrenched analytical workflows in a conservative industry, and technical/regulatory execution risks associated with delivering a flawless, compliant software platform capable of generating submission-ready data.
Competition from large instrument vendors and potential shifts in therapeutic modality popularity also pose threats.

Competitive Landscape

RNAnalytics competes with established particle characterization instrument companies (e.g., Malvern Panalytical, Horiba) that offer proprietary software, and with CROs providing analytical services. Its differentiation lies in the integrated hardware/software approach, a specific focus on RNA/LNP resolution, and a CTD-native data model designed for regulatory submission efficiency, rather than being a general-purpose analysis tool.